TNFRSF9 and neoplasm: In that study, anti-CD137 treated mice differed from control mice in the following respects: (1) Tumour bearing mice treated with adoptively transferred CTLs plus anti-CD137 (ACT+mAb) showed improved tumour control compared to counterparts treated with CTL but no antibody (ACT-only).